HomeCompareFOJCF vs PFE

FOJCF vs PFE: Dividend Comparison 2026

FOJCF yields 6.13% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FOJCF wins by $49.9K in total portfolio value
10 years
FOJCF
FOJCF
● Live price
6.13%
Share price
$24.66
Annual div
$1.51
5Y div CAGR
27.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$99.4K
Annual income
$25,542.24
Full FOJCF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — FOJCF vs PFE

📍 FOJCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFOJCFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FOJCF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FOJCF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FOJCF
Annual income on $10K today (after 15% tax)
$521.17/yr
After 10yr DRIP, annual income (after tax)
$21,710.90/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $609.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FOJCF + PFE for your $10,000?

FOJCF: 50%PFE: 50%
100% PFE50/50100% FOJCF
Portfolio after 10yr
$74.5K
Annual income
$25,900.48/yr
Blended yield
34.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

FOJCF
No analyst data
Altman Z
2.7
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FOJCF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFOJCFPFE
Forward yield6.13%6.13%
Annual dividend / share$1.51$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR27.2%13.2%
Portfolio after 10y$99.4K$49.6K
Annual income after 10y$25,542.24$26,258.71
Total dividends collected$70.0K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FOJCF vs PFE ($10,000, DRIP)

YearFOJCF PortfolioFOJCF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,480$779.91$9,153$693.39+$2.3KFOJCF
2$13,348$1,064.36$8,593$849.25+$4.8KFOJCF
3$15,753$1,471.17$8,336$1,066.78+$7.4KFOJCF
4$18,920$2,064.10$8,437$1,384.80+$10.5KFOJCF
5$23,192$2,947.04$9,013$1,875.40+$14.2KFOJCF
6$29,109$4,294.32$10,306$2,680.72+$18.8KFOJCF
7$37,555$6,407.66$12,820$4,101.38+$24.7KFOJCF
8$50,011$9,827.29$17,673$6,826.70+$32.3KFOJCF
9$69,069$15,557.39$27,543$12,591.86+$41.5KFOJCF
10$99,446$25,542.24$49,560$26,258.71+$49.9KFOJCF

FOJCF vs PFE: Complete Analysis 2026

FOJCFStock

Fortum Oyj, together with its subsidiaries, engages in the generation and sale of electricity and heat in the Nordic countries, Germany, the United Kingdom, Russia, the Netherlands, the Baltic Rim area, and internationally. The company's Generation segment generates power through nuclear, hydro, wind, and thermal resources; and provides power portfolio optimization, trading, and industrial intelligence, as well as nuclear services. Its City Solutions develops solutions in the areas of heating, cooling, waste-to-energy, biomass, and other circular economy solutions, as well as solar power production. The company's Consumer Solutions segment engages in electricity and gas retail businesses, including the provision of invoicing and customer services; and electricity and related value-added products, as well as digital services. This segment serves approximately 2.4 million customers. Its Russia segment generates and sells power and heat. The company's Uniper segment engages in the power generation business, as well as energy trading and optimization activities. Fortum Oyj was founded in 1998 and is headquartered in Espoo, Finland.

Full FOJCF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this FOJCF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FOJCF vs SCHDFOJCF vs JEPIFOJCF vs OFOJCF vs KOFOJCF vs MAINFOJCF vs JNJFOJCF vs MRKFOJCF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.